A Phase 1 interventional study of NM-101 and Placebo in Parkinson Disease, sponsored by Neuramedy Co. Ltd.. Status unknown at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-30.
Sponsored by Neuramedy Co. Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 114th largest by planned enrollment of the 183 interventional ones that give a count, is one of 20 that started in 2023, is one of 26 in phase 1, and was the 189th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Northumbria University · Sites in United Kingdom
Ages 50+
Hoffmann-La Roche · Sites in United Kingdom, United States, China and 2 more countries
Ages 40–85
Heriot-Watt University · Sites in United Kingdom
Ages 18+
Queen's University, Belfast · Sites in United Kingdom
Ages 18+
University Hospital Tuebingen · Sites in United Kingdom, France, Germany and 4 more countries
Ages 35–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 48 · Phase 3 46 · Phase 4 6
First in 1999; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 80 across the 183 interventional studies, 100 across the 62 observational. Of the 152 that completed or were terminated, 45 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 246 have an industry lead sponsor. The 10 most frequent:
Neuramedy Co. Ltd. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Neuramedy Co. Ltd. has 1 study filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05986643University of LeicesterBrain Training to Improve Balance in Parkinson's Disease | 2026-12 |
| NCT05635409Region SkaneA Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease | 2027-01 |
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
| NCT07882108Cambridge University Hospitals NHS Foundation TrustGinger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease | 2027-03-01 |
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase I, double-blind, randomised, two-part, single-ascending dose (Part 1) and multiple-ascending dose (Part 2) study of NM-101 in healthy males and healthy females of non-childbearing potential
NM-101 is an anti-TLR2 antibody which may have clinical efficacy in Parkinson's disease patients. This Phase I study aims to assess the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of NM-101 in healthy males and healthy females of non-childbearing potential. A total of 56 subjects (8 per cohort) are planned to be enrolled.
Subjects will be randomly assigned to recieve NM-101 or placebo in a 3:1 ratio. The study will be in 2 parts: Part 1 will consist of 3 single-dose cohorts; Part 2 will consist of 4 multiple-dose cohorts.
In Part 1, sentinel dosing will be applied. In each cohort, 1 subject will be randomised to receive NM-101 and 1 subject will be randomised to receive placebo ahead of dosing in the remaining 6 subjects. The dose for Cohort 1 is 20 mg/kg NN-101. The predicted doses for Cohorts 2 and 3 are 40 mg/kg and 60 mg/kg NM-101, respectively (dependent on a blinded interim review of the safety, tolerability and PK data). Blood samples will be collected at regular intervals for PK analysis and safety from Day 1 until Day 42.
In Part 2, sentinel dosing will not be applied. Each subject will receive 4 doses of NM-101 or placebo over the course of 3 months. Dosing may occur in parallel to the conduct of Part 1. The doses administered will be selected based on emerging safety, tolerability and PK data from preceding groups in Part 1. The predicted NM-101 doses are: 10 mg/kg for Cohort 4; 20 mg/kg for Cohort 5; 40 mg/kg for Cohort 6; 60 mg/kg for Cohort 7. In Cohorts 5 to 7, subjects will undergo a lumbar puncture to assess NM-101 concentrations in the cerebrospinal fluid. Blood samples will be collected at regular intervals for PK analysis and safety from Day 1 until Day 127.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
and Compliance
Must be willing and able to communicate and participate in the whole study
Demographics and
Must agree to adhere to the contraception requirements
Baseline Characteristics
(BMI) of 18.0 to 32.0 kg/m2 as measured at screening
Other
Exclusion Criteria:
Medical/Surgical History and Mental Health
Evidence or history of clinically significant back pain, back pathology and/or back injury (e.g. degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulties in the conduct of a lumbar puncture (Part 2 only)
Physical Examination
Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator or delegate at screening
Diagnostic Assessments
Females of including those who are pregnant or lactating (all female subjects must have a negative highly sensitive serum pregnancy test)
Prior Study Participation
Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
Prior and Concomitant Medication
Have taken non-steroidal anti-inflammatory drugs or other drugs that affect coagulation or function within 14 days prior to scheduled lumbar puncture (Part 2 only)
Lifestyle Characteristics
Confirmed positive drugs of abuse test result
Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ascending doses of NM-101. IV infusion over 2 hours
Drug: NM-101
IV infusion over 2 hours
Drug: Placebo
In Part 1, each cohort will receive a single dose at one of three dose levels (3 cohorts). In Part 2, each cohort will receive multiple doses at one of four dose levels (4 cohorts).
Also known as: Tomarilimab, OPN-305 (formerly)
Placebo solution for infusion
Safety of NM-101: Incidence of Treatment-Related Adverse Events by Severity
A treatment related adverse event is defined as a clinical event with plausible time relationship to NM-101 administration and that cannot be explained by concurrent disease or other drugs or chemicals
Time frame: up to 4 months
PK Parameter
maximum concentration (Cmax)
Time frame: up to 4 months
PK Parameter
time of the maximum measured concentration (Tmax)
Time frame: up to 4 months
PK Parameter
area under the concentration-time curve from time (AUC)
Time frame: up to 4 months
PK Parameter
First order rate constant associated with the terminal portion of the curve (Lambda-z)
Time frame: up to 4 months
PK Parameter
terminal elimination half life (t1/2)
Time frame: up to 4 months
PK Parameter
clearance (CL)
Time frame: up to 4 months
PK Parameter
Volume of distribution based on the terminal phase (Vz)
Time frame: up to 4 months
PK Parameter
Volume of distribution at steady state (Vss)
Time frame: up to 4 months
Cerebrospinal Fluid (CSF) Concentrations of NM-101
Quantification of NM-101 24 h after the dose only in Cohorts 5 to 7
Time frame: Day 2 or Day 86
Immunogenicity of NM-101
Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101 Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101 Quantification of NM-101 anti-drug antibodies pre-dose and after each dose of NM 101
Time frame: up to 4 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for May 2023; primary completion for May 2024, 12 months later.
Of 127 industry-sponsored phase 1 interventional studies under Parkinson Disease, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 12 months is above that.
Counting every sponsor, half of 204 studies reached it within 18 months; a quarter within 5 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuramedy Co. Ltd.